Elevated IL-8, TNF-α, and MCP-I in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival

Simple item page
dc.contributor.authorSharma, J.
dc.contributor.authorGray, K.
dc.contributor.authorHarshman, L.
dc.contributor.authorEvan, C.
dc.contributor.authorNakabayashi, M.
dc.contributor.authorFichorova, R.
dc.contributor.authorRider, J.
dc.contributor.authorMucci, L.
dc.contributor.authorKantoff, P.
dc.contributor.authorSweeney, C.
dc.date.issued2014
dc.description.abstractAbstract not available
dc.description.statementofresponsibilityJaya Sharma, Kathryn P. Gray, Lauren C. Harshman, Carolyn Evan, Mari Nakabayashi, Raina Fichorova, Jennifer Rider, Lorelei Mucci, Philip W. Kantoff, and Christopher J. Sweeney
dc.identifier.citationProstate, 2014; 74(8):820-828
dc.identifier.doi10.1002/pros.22788
dc.identifier.issn0270-4137
dc.identifier.issn1097-0045
dc.identifier.orcidSweeney, C. [0000-0002-0398-6018]
dc.identifier.urihttp://hdl.handle.net/2440/93474
dc.language.isoen
dc.publisherWiley
dc.rights© 2014 Wiley Periodicals, Inc.
dc.source.urihttps://doi.org/10.1002/pros.22788
dc.subjectelevated IL-8; TNF-α and MCP-1; inflammation; prostate cancer
dc.titleElevated IL-8, TNF-α, and MCP-I in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival
dc.title.alternativeElevated IL-8, TNF-alpha, and MCP-I in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications